AI Article Synopsis

Article Abstract

The aim of this study was to investigate the clinical value of fluorescence in situ hybridization (FISH) in detecting the genomic aberration of chronic lymphocytic leukemia (CLL). FISH was used for 32 patients who were newly diagnosed as CLL. Five types of fluorescence probes with labeled DNA probes were included as sequence specific probes D13S25 for 13q14.3, P53 for 17p13.1, ATM for 11q22.3, RB1 for 13q14 and chromosomes 12. Meanwhile, FISH was used to detect IGH/CCND1 fusion gene in 10 CLL patients with untypical immunophenotypes. The results showed that out of 32 patients, 26 cases (81.3%) were abnormal including 14 cases of D13S25 deletion, 11 of RB1 deletion, 9 of trisomia 12, 6 cases of P53 deletion, and 1 of ATM deletion. 12 cases showed 1 kind of genomic aberration, including 7 cases of trisomia 12, 3 cases of D13S25 deletion, 1 of P53 deletion, 1 of ATM deletion. 11 eases displayed 2 kinds of abnormalities. Out of 11 cases, 7 were D13S25/RB1 deletion, 4 were of P53 deletion, and 3 cases had 3 kinds of abnormalities. Among 10 patients with CD5(+)CD23(-), two were positive with IGH/CCND1. It is concluded that the FISH can improve the detecting of chromosomal abnormalities in CLL, and every abnormality has its special feature. Detection of IGH/CCND1 seems important in diagnoses of CLL.

Download full-text PDF

Source

Publication Analysis

Top Keywords

p53 deletion
12
deletion
9
fluorescence situ
8
situ hybridization
8
chronic lymphocytic
8
genomic aberration
8
cases
8
including cases
8
cases d13s25
8
d13s25 deletion
8

Similar Publications

IP6K1 rewires LKB1 signaling to mediate hyperglycemic endothelial senescence.

Diabetes

January 2025

Institute for Developmental and Regenerative Cardiovascular Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.

Diabetes is a major risk factor for cardiovascular disease, but the molecular mechanisms underlying diabetic vasculopathy have been elusive. Here we report that inositol hexakisphosphate kinase 1 (IP6K1) mediates hyperglycemia-induced endothelial senescence by rewiring the liver kinase B1 (LKB1) signaling from activating the adenosine monophosphate-activated protein kinase (AMPK) pathway to the p53 pathway. We found that hyperglycemia upregulated IP6K1, which disrupts the Hsp/Hsc70 and carboxyl terminus of Hsc70-interacting protein (CHIP)-mediated LKB1 degradation, leading to increased expression levels of LKB1.

View Article and Find Full Text PDF

Wip1 phosphatase activator QGC-8-52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells.

Drug Resist Updat

December 2024

Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200123, China. Electronic address:

PP2C serine-threonine phosphatase Wip1 plays an important role in normal tissue homeostasis, stress signaling and pathogenesis of various human diseases. It is an attractive drug target for cancer treatment and inhibition of its expression or activity constitute a novel therapeutic intervention strategy to prevent the development of various cancers. However, previous strategies for Wip1 suppression may be ineffective in cancers lacking p53.

View Article and Find Full Text PDF

Background: Juvenile granulosa cell tumor (JGCT) of the ovary is a rare tumor with distinct clinicopathological and hormonal features primarily affecting young women and children. We conducted a complex clinicopathological, immunohistochemical, and molecular analysis of five cases of JGCT.

Methods: The immunohistochemical examination was performed with 32 markers, including markers that have not been previously investigated.

View Article and Find Full Text PDF

Mutant p53-Mediated Tumor Secretome: Bridging Tumor Cells and Stromal Cells.

Genes (Basel)

December 2024

Laboratory of Molecular Genetics of Aging & Tumor, Medical School, Kunming University of Science and Technology, Chenggong Campus, 727 South Jingming Road, Kunming 650500, China.

The tumor secretome comprises the totality of protein factors secreted by various cell components within the tumor microenvironment, serving as the primary medium for signal transduction between tumor cells and between tumor cells and stromal cells. The deletion or mutation of the gene leads to alterations in cellular secretion characteristics, contributing to the construction of the tumor microenvironment in a cell non-autonomous manner. This review discusses the critical roles of mutant p53 in regulating the tumor secretome to remodel the tumor microenvironment, drive tumor progression, and influence the plasticity of cancer-associated fibroblasts (CAFs) as well as the dynamics of tumor immunity by focusing on both secreted protein expression and secretion pathways.

View Article and Find Full Text PDF

Background: Prostate cancer is the most common diagnosed tumor and the fifth cancer related death among men in Europe. Although several genetic alterations such as ERG-TMPRSS2 fusion, MYC amplification, PTEN deletion and mutations in p53 and BRCA2 genes play a key role in the pathogenesis of prostate cancer, specific gene alteration signature that could distinguish indolent from aggressive prostate cancer or may aid in patient stratification for prognosis and/or clinical management of patients with prostate cancer is still missing. Therefore, here, by a multi-omics approach we describe a prostate cancer carrying the fusion of TMPRSS2 with ERG gene and deletion of 16q chromosome arm.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!